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Originally called retinoid X receptor interacting protein 14 (RIP14), the farnesoid X receptor (FXR) was renamed
after the ability of its rat form to bind supra-physiological concentrations of farnesol. In 1999 FXR was
de-orphanized since primary bile acids were identified as natural ligands. Strongly expressed in the liver and
intestine, FXR has been shown to be the master transcriptional regulator of several entero-hepatic metabolic
pathways with relevance to the pathophysiology of conditions such as cholestasis, fatty liver disease,
cholesterol gallstone disease, intestinal inflammation and tumors. Furthermore, given the importance of FXR
in the gut-liver axis feedbacks regulating lipid and glucose homeostasis, FXR modulation appears to have
great input in diseases such as metabolic syndrome and diabetes. Exciting results from several cellular and
animal models have provided the impetus to develop synthetic FXR ligands as novel pharmacological agents.
Fourteen years from its discovery, FXR has gone from bench to bedside; a novel nuclear receptor ligand is
going into clinical use.
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Introduction
Nuclear receptors (NRs) are ligand-activated transcription
factors that, in response to lipophilic hormones, vitamins,
and dietary lipids, regulate many aspects of mammalian
physiology, including development, reproduction and
metabolism [Chawla et al., 2001; Mangelsdorf et al.,
1995].
In 1995, using a two-hybrid yeast system, Seol et al.
identified several mouse liver cDNA sequences encoding
for proteins able to interact with the ligand binding domain
(LBD) of the human nuclear receptor RXRα [Seol et al.,
1995]. Among these proteins, a novel protein termed
RIP14 (RXR-interacting protein 14) turned out to be
unique in its interaction with RXRα. By northern blot
analysis, RIP14 expression was detected in kidney and
liver, and two isoforms of RIP14 proteins were
discriminated. RIP14-1 had a 4-amino acid (MYTG)
central insertion, while RIP14-2 presented a 38-amino
acid NH2-terminal extension. RIP14 was able to bind as
a heterodimer with RXRα to previously identified hormone
responsive elements (HREs), such as the retinoic acid
response element (RARE) from the promoter of the
RARβ2 isoform and the ecdysome response element
(EcRE) from the Drosophila hsp27 promoter.The
RIP14-RXRα heterodimer was shown to bind to direct
repeats with a 5-, 4- and 2-bp spacer (DR5, DR4 and
DR2, respectively) and inverted repeats IR0 and IR1, but
not to DR0, DR1, DR3, IR2 and IR5. Importantly, the fact
that, in reporter assays, RIP14 was unable to
transactivate a reporter containing multiple copies of the
βRARE, suggested that RIP14 activity was
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was unknown at that time. Later, in 1995, Forman et al.
were able to clone from a rat liver cDNA library the rat
homolog of the mouse RIP14 and they showed that
farnesol, an intermediate of the mevalonate pathway,
was able to activate rat RIP14 at the concentration of 50
µM [Forman et al., 1995]. For this reason, rat RIP14 was
renamed farnesoid X receptor (FXR) and its expression
was detected in the liver, kidney, intestine and adrenal
cortex. However, supra-physiological concentrations of
farnesol were required to induce FXR activity.
In 1999, FXR was “de-orphanized” when it was
demonstrated that primary bile acids (BAs) were the
endogenous ligands for FXR [Makishima et al., 1999;
Parks et al., 1999;Wang et al., 1999]. Indeed, FXR was
also named BAR (bile acid receptor). BAs were shown
to activate FXR at physiological concentrations using an
in vitro coactivator recruitment assay. BAs are steroid-end
products of cholesterol catabolism and are classified as
either primary BAs (chenodeoxycholic acid (CDCA) and
cholic acid (CA)), synthesized from cholesterol in the liver,
or secondary BAs (deoxycholic acid (DCA) and lithocholic
acid (LCA)), produced by intestinal bacteria from primary
BAs.The majority of circulating BAs are conjugated with
glycine or taurine, by a process occurring in the liver (for
details about BA homeostasis, see below).The chemical
structure of BAs is shown in Figure 1.
The generation of FXR knock-out mice revealed a clear
role for FXR in vivo as the master regulator of BA
homeostasis [Kok et al., 2003; Sinal et al., 2000].The
generation of FXR knock-out mice was a breakthrough
for understanding the role of FXR in many BA-related
physiological and pathophysiological conditions. Loss of
FXR resulted in an enlarged BA pool size as a
consequence of increased expression of CYP7A1, the
rate-limiting enzyme for the conversion of cholesterol to
BAs. Interestingly, FXR knock-out mice also exhibited
elevated levels of cholesterol and triglycerides in both
plasma and liver.These observations suggested a key
role for FXR also in lipid metabolism. Indeed, it was
shown in 2004 that FXR activation is required to reduce
sterol-regulatory-element-binding-protein-1c (SREBP1-c)
expression, a key molecule involved in lipogenesis
[Watanabe et al., 2004]. In the same year, it was shown
that the loss of FXR in mice predisposes to gallstone
disease, while its activation may ameliorate this condition
by restoring the right biliary BA:cholesterol ratio
[Moschetta et al., 2004]. Before these findings, the use
of FXR as a target for the management of cholestasis
was also proposed [Liu et al., 2003].
In addition to BA and lipid metabolism, it has been shown
that FXR also plays an important role in glucose
homeostasis by improving insulin sensitivity and glucose
tolerance in diabetic mice [Ma et al., 2006; Zhang et al.,
2006a]. Furthermore, in the intestine, FXR is required to
protect the epithelium by preventing bacterial overgrowth
and consequent mucosa deterioration and bacterial
translocation [Inagaki et al., 2006]. Finally, FXR also plays
a role in liver regeneration [Huang et al., 2006], and both
hepatic [Kim et al., 2007b;Yang et al., 2007] and intestinal
tumorigenesis [Maran et al., 2009; Modica et al., 2008].
By regulating BAs, lipid and glucose homeostasis, FXR
affects many aspects of our metabolism.This makes FXR
an attractive pharmacological target for the management
of diseases ranging from hyperlipidemia to diabetes, from
cholestasis to enterohepatic tumors.
FXR gene and protein structure
Two FXR genes are known and are referred to as FXRα
(NR1H4) and FXRβ (NR1H5). FXRβ is a pseudogene in
humans, while it is expressed in rodents, rabbits and
dogs. It has been proposed to be a lanosterol sensor,
although its physiological function remains to be
established [Otte et al., 2003].The FXRα gene is
conserved from fish (teleost fish, Fugu rubriens) to
humans, which suggests a crucial role for this gene in
many species [Maglich et al., 2003]. In humans and mice,
FXRα is highly expressed in the liver, intestine, kidney
and adrenal gland, while low expression has been
detected in the heart and adipose tissue [Zhang et al.,
2003].The FXRα gene is mapped to human chromosome
12q23.1 and mouse chromosome 10c.2, and it is
composed of 11 exons and 10 introns (Figure 2). As a
single gene, FXRα encodes four transcript isoforms in
both humans and mice, FXRα1 (RIP14-2), FXRα2,
FXRα3, and FXRα4 (RIP14-1), as a result of alternative
splicing of exon 5 and the use of two distinct promoters
that initiate transcription from either exon 1 (5' promoter)
or exon 3 (3' promoter) [Huber et al., 2002; Zhang et al.,
2003].The 5' or 3' promoters of the FXRα gene regulate
the expression of FXRα1 and FXRα2 or FXRα3 and
FXRα4 transcripts, respectively. Unlike FXRα2 and
FXRα4, FXRα1 and FXRα3 transcripts contain four amino
acids (MYTG) immediately adjacent to the DNA-binding
domain (DBD) in a region referred to as the hinge domain.
Notably, the four FXRα isoforms are expressed in a
tissue-specific manner and few FXRα target genes are
regulated in an isoform-dependent manner [Lee et al.,
2005; Lee et al., 2006; Zhang et al., 2003]. FXRα1 and
FXRα2 are moderately expressed in the adrenal gland
and ileum, while FXRα3 and FXRα4 are highly expressed
in the ileum, moderately in the kidney and at low levels
in the duodenum and jejunum. Some genes such as the
ileal bile acid binding protein (IBABP) and fibroblast
growth factor 19 (FGF19) are more responsive to the
FXRα2 and FXRα4 isoforms (lacking the MYTG motif)
than FXRα1 and FXRα3 isoforms [Zhang et al., 2003].
As members of the NR superfamily, the four FXRα
proteins (grouped hereafter with the term of FXR)
encoded by the single FXRα gene (referred to hereafter
as FXR) present a typical NR structure organized in a
highly conserved DBD, a poorly conserved N-terminal
domain and a moderately conserved C-terminal LBD
(Figure 2). In the absence of BAs, FXR sits on the HRE
of its target genes as a heterodimer with the obligate
partner RXR, in association with corepressor proteins.
Located in the DBD, two cysteine-coordinated Zn
2+ finger
motifs are responsible for DNA binding and dimerization.
The FXR/RXR heterodimer mainly binds IR1 (two
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Review The bile acid sensor FXRFigure 1.  Structure and hydrophobic/hydrophilic profile of the most common bile acids. Cholic acid (CA) and chenodeoxycholic acid (CDCA)
are primary BAs. Deoxycholic acid (DCA) and lithocholic acid (LCA) are secondary BAs. Ursodeoxycholic acid (UDCA) is a primary BA predominantly
produced in bears. Hydroxyl groups that are in α-orientation are located below the steroid nucleus and are axial to the plane of the steroid nucleus.
Hydroxyl groups that are in β-orientation are located above the steroid nucleus and are equatorial to the plane of the steroid nucleus.The hydrophobicity
increases as follows: UDCA, CA, CDCA, DCA, LCA.
canonical AGGTCA inverted repeats with one space
nucleotide) and can be activated by either FXR- or
RXR-specific ligands. Besides IR-1, other HREs for FXR
are direct repeated such as DR-1 and everted repeated
such as ER-8. Ligand binding induces conformational
changes of FXR that determine the release of corepressor
proteins such as NCor (nuclear corepressor), and the
recruitment of coactivator proteins, such as SRC-1
(steroid receptor coactivator 1), PGC1α
(peroxisome-proliferator-receptor (PPAR)-γ
coactivator-1α) [Savkur et al., 2005b; Zhang et al., 2004],
CARM-1 (coactivator associated arginine (R) methyl
transferase-1) [Ananthanarayanan et al., 2004; Bauer et
al., 2002], PMRT-1 (protein arginine (R) methyl
transferase-1) [Rizzo et al., 2005], and DRIP-205
(vitamin-D-receptor-interacting protein-205) [Pineda Torra
et al., 2004]. In addition to the LBD, the C-terminal region
of FXR contains a ligand-dependent transactivation
domain, AF2, that along with a ligand-independent
transactivation domain, AF1, in the N-terminal region,
interacts with coregulatory proteins.
The LBD of FXR contains a hydrophobic pocket that
accommodates lipophilic molecules such as BAs. Crystal
structures of the human and rat FXR LBD in complex with
two CDCA derivatives ((3-deoxy-CDCA and
6α-ethyl-chenodeoxycholic acid (6α-ECDCA)), the
synthetic ligand fexaramine and a coactivator peptide
have been solved [Downes et al., 2003; Mi et al., 2003],
showing that the amino acids involved in the ligand
binding are conserved between human and rat. Moreover,
these studies revealed that, beside the classical features
of the LBD of NRs, such as its general organization in a
12-α helix bundle, the LBD of FXR presents peculiar
characteristics. Similar to other NRs, the LBD of FXR acts
as a molecular switch after ligand binding, undergoing
conformational changes that result in the recruitment of
coactivator proteins by forming a “charge clamp” and a
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Review The bile acid sensor FXRFigure 2.  Structure and transcripts of the mouse FXRα gene. A) Similar to the human FXRα gene (mapped to chromosome 12 (q23.1)), the
mouse FXRα gene (mapped to chromosome 10 (c2)) is characterized by 11 exons and two distinct promoters that initiate transcription from either exon
1 or exon 3. Four distinct transcripts, FXRα1, FXRα2, FXRα3, FXRα4 are generated from the same gene, as a consequence of the alternative splicing
of exon 5 and the use of two distinct promoters. ATG indicate the translational starting sites. In blue is indicated the alternative splicing of the 12 bp of
exon 5 that encode the MYTG motif in the hinge region.The four FXRα transcripts are shown with the different classical NR receptor domains color
coded. B) Upon ligand binding, FXRα binds to FXR response elements (FXRE) of its target genes as a heterodimer with RXR. Examples of consensus
sequences are shown.
hydrophobic groove that interacts with the LXXLL motifs
of the coactivators [Downes et al., 2003; Mi et al., 2003].
Unlike steroid NRs, the LBD of FXR accommodates the
steroid nucleus of its ligands in a reverse orientation.
Moreover, a second docking site for the LXXLL motifs
has been found in the LBD of FXR [Mi et al., 2003].
Consequently, a coactivator with a single LXXLL motif
binds to the FXR LBD with low affinity, while coactivators
with two or more LXXLL motifs exhibit higher affinity.The
FXR LBD binds the two LXXLL motifs in an anti-parallel
manner with one motif located in the classical groove and
blocked by a “charge clamp”, and the other motif located
in the helix 3, without being secured by a “charge clamp”.
It has been suggested that the FXR LBD uses both LXXLL
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one of them increasing its affinity for the coactivator.
However, this is a hypothesis that needs to be confirmed.
Genetic variability of FXR
The paucity of nonsynonymous single nucleotide
polymorphisms (SNPs) in FXR indicates that this is an
important and evolutionarily conserved gene.Two
nonsynonymous SNPs have been detected in exon 6 at
the level of the hinge region (C643T and G646T). In
Chinese- and Hispanic-Americans, two synonymous
polymorphisms have been also detected in exon 7
(C783T) and 11 (C1341T), although with very low
genotypic frequency. Conversely, a G-1T polymorphism
located in the Kozak consensus motif of the exon 3
sequence flanking the start codon is relatively common
among European-, Chinese-, African- and
Hispanic-Americans [Marzolini et al., 2007].
Although this SNP results in reduced transactivation
activity, it is not clear whether this effect is due to
decreased transcription/translation or the formation of a
low-activity, translational variant. Consistent with the in
vitro studies, reduced hepatic expression of the FXR
target gene small heterodimer partner (SHP) was
observed [Marzolini et al., 2007].While it remains unclear
how the decreased expression of SHP in subjects with
G-1T polymorphism would manifest, studies in SHP
knock-out mice showed that the lack of SHP leads to
increased hepatic insulin sensitivity [Ballatori et al., 2005].
Moreover, Japanese patients with mutations in the SHP
gene present hypertriglyceridemia and mild obesity
[Nishigori et al., 2001].
It is worth noting that the expression of another FXR
target gene, the ATP-binding cassette (ABC) transporter
bile salt export pump (BSEP/ABCB11) was not changed.
Thus, if there is an effect of FXR polymorphisms, this
seems to be target gene-dependent.
It has been suggested that mutations in the FXR gene
may also predispose subjects to intrahepatic cholestasis
of pregnancy (ICP). Four heterozygous variants have
been identified in patients with ICP [Van Mil et al., 2007],
with three of them showing a functional defect in
translational efficiency or activity. Moreover, an FXR
haplotype (NR1H4_1) in the Mexican population has been
associated with gallstone disease [Kovacs et al., 2008].
Taken together, the few data available on FXR
polymorphism indicate that this is an important and
evolutionarily-conserved gene with rare relevant
mutations.
Natural and synthetic FXR ligands
Naturally-occurring BAs differ in minor structural
modifications. Nevertheless, these differences have
impact on the affinity for FXR and ability to activate it.
Taking advantage of the knowledge of the
structure-activity relationship of BAs for the FXR LBD,
semisynthetic and synthetic molecules have been made
to obtain more selective and potent FXR activators than
BAs. Examples of semisynthetic, synthetic and natural
ligands are reported in Figure 3.
Bile acids and semisynthetic bile acid
derivatives
The chemical structure of BAs consists of a steroid
nucleus with an acidic side chain (Figure 1).They are
amphipatic molecules with a unique shape characterized
by a concave hydrophilic face (α face) and a convex
hydrophobic face (β face).The hydrophobic pocket of the
FXR LBD interacts with BAs mainly through the β face.
The α face contains several hydroxyl groups in the 3, 7
and/or 12α positions that impacts on the ability to activate
FXR [Fujino et al., 2004]. Optimal FXR activation through
ligand binding requires the proper positioning of helix 3
versus helix 12 in order to generate the LXXLL docking
groove.The 7α-hydroxy group confers high capacity to
CDCA and synthetic ligands, such as fexaramine and
6α-ECDCA (see below), to activate FXR by inducing a
highly stable interaction between helix 3 and helix 12,
resulting in a strong agonist activity. Conversely, the
absence of a 7α-hydroxy group, in the case of DCA and
LCA, compromises stable coactivator recruitment and
results in partial agonistic properties. Finally, the FXR
LBD cannot accommodate a 12α-hydroxy group and
consequently, CA and DCA have low affinity for FXR.
The hydrophobic pocket of the LBD contains a series of
hydrophobic cavities that can be exploited to first generate
further contacts, and then to increase the affinity of the
ligand for the FXR LBD.Thus, 6α-ECDCA has a higher
affinity than CDCA for FXR. Notably, the carboxyl
extremity of BAs is oriented towards the entry of the
hydrophobic pocket of the LBD, indicating why conjugated
BAs conserve a high affinity for FXR and the ability to
activate it [Pellicciari et al., 2006]. Structural modifications
of the carboxyl terminus of BAs may result in altered FXR
activity.
The agonist or antagonist properties of a NR ligand are
generally evaluated by the recruitment to the LBD of an
SRC-1 derivate peptide containing the typical LXXLL motif
in a cell-free fluorescence energy transfer (FRET) assay.
In this way, it was shown that CDCA and its glycol- and
tauro-conjugates were able to recruit a peptide from the
SRC-1 coactivator (EC50=3.5 µM) to the FXR LBD
[Makishima et al., 1999; Parks et al., 1999; Pellicciari et
al., 2002;Yu et al., 2002]. On the contrary, DCA, LCA,
CA and their conjugates were not able to induce
significant coactivator recruitment up to the concentration
of 1000 µM (100 µM for DCA), but importantly, they
interfered in a dose-dependent fashion with the ability of
CDCA to induce FXR-SRC-1 interaction [Lew et al., 2004;
Makishima et al., 1999; Parks et al., 1999;Yu et al.,
2002].These data indicate that DCA, LCA, CA and their
conjugates act as partial antagonists in this assay. Next,
LCA was proposed as an FXR antagonist with partial
agonist activity because of its ability to antagonize the
CDCA promoting association between FXR and SRC-1
in the cell-free assay, which correlated with antagonist
activity on FXR transactivation and the partial induction
of BSEP [Yu et al., 2002]. Finally, ursodeoxycholic acid
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Review The bile acid sensor FXRFigure 3.  FXR ligands. Examples of FXR semisynthetic (6α-ECDCA), synthetic (GW4064, Fexeramine, AGN-29, AGN-31, AGN-34) and natural
(Z-4,17(20)-pregnadiene-3,16-dione and E-4,17(20)-pregnadiene-3,16-dione) ligands.
(UDCA), a hydrophilic BA found in large quantities in bear,
was shown to act as a very weak FXR agonist for the
induction of BSEP expression and reduction of CYP7A1
expression [Lew et al., 2004].
In addition to cell-free assays, cell-based assays were
carried out to evaluate the ability of different BAs to
activate FXR. Initial transfection studies were consistent
in indicating CDCA as the most potent FXR activator
(EC50=50 µM), while DCA and LCA activated FXR with
a lower efficacy than CDCA [Makishima et al., 1999].
Hydrophilic unconjugated BAs, such as CA and UDCA,
could not activate FXR, and moreover, UDCA turned out
to be a partial antagonist, able to inhibit activation by
CDCA [Campana et al., 2005]. Interestingly, in the same
transfection assays, the glycol- and tauro-CDCA, -DCA
and -LCA were likewise unable to activate FXR. After
cotransfection of the apical sodium-dependent BA
transporter (ASBT, (SLC10A2)), an apical protein required
for the active uptake of conjugated BAs, the ability of
glycol- and tauro-CDCA, -DCA and -LCA were likewise
unable to activate FXR. After ASBT cotransfection, CA
and its conjugates were also able to cross the cell
membrane and activate FXR [Wang et al., 1999].
It is worth noting that apart from the cotransfection assays
where ASBT was present and a rat form of FXR was used
[Wang et al., 1999], there is no convincing evidence
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FXR LBD is not perfectly conserved between species.
This makes, for instance, the mouse FXR LBD much
more responsive to CA than its human counterpart [Cui
et al., 2002]. In line with CA being of more physiological
importance in mice, they do not have CDCA, the most
potent natural activator of human FXR, which is converted
to β-MCA.
Taken together, the cell-free and cell-based assays
indicate weak correlation between the affinity of BAs for
FXR, their ability to induce FXR LBD coactivator
interaction and their biological activity.Thus, cell-free
assays for coactivator recruitment analysis are not
predictive of the transcriptional outcome or the
transcriptional outcome depends on many parameters,
such as DNA binding sequences and dimerization
partners, as suggested for FXR [Lew et al., 2004] and
other NRs [Molavi et al., 2006]. It is also possible that the
SRC-1 coactivator assay is not the best investigative
model.
Chemical manipulations of the side chain and the steroid
nucleus of BAs have been exploited to generate
semisynthetic BA derivatives that could be more potent
FXR activators.The use of these semisynthetic molecules
in transcriptional and ligand-binding assays has generated
important information regarding the structure-activity
relationship, confirming to some extent the
crystallographic studies on the structure of the FXR LBD.
The conversion of the 24-carboxyl group of CDCA and
CA to the corresponding alcohol, generated compounds
with FXR ligand-like activities, similar to CDCA [Fujino et
al., 2004]. It is worth noting that while CA can activate
FXR only if the ASBT protein is expressed, the
corresponding alcohol derivative can activate FXR in the
absence of ASBT, indicating that the conversion of the
24-carboxyl group into the corresponding alcohol
increases its transport across the cell membrane by
passive diffusion.
With respect to the steroid nucleus of BAs, the importance
of the C3 and C12 hydroxyl groups was also addressed
[Fujino et al., 2004].The corresponding 3β and 12β
epimers of DCA and LCA were shown to be completely
inactive in transactivation assays. Similarly, the
introduction of a hydrophobic alkyl group at the 3β and
12β position made the BA derivatives inactive. It is
noteworthy that
3β,7α-dihydroxy-3α-methyl-5β-cholan-24-oic acid was
able to activate FXR as well as CDCA, indicating that the
2α hydroxyl group of CDCA is not involved in FXR
activation.
The ability to activate FXR by early intermediates
produced in the BA biosynthetic pathway was also
evaluated [Nishimaki-Mogami et al., 2004].The molecules
maintaining an intact cholesterol side chain were inactive,
while cholestanoic acids, as well as 25- and
26-hydroxylated bile alcohols, were able to activate FXR
to the same extent as CDCA. Since these intermediates
in the BA biosynthetic pathway are evolutionary
precursors of BAs in mammals, it may be that the affinity
for them to FXR has been conserved during evolution.
In a small library of BA derivatives, obtained by
modification of the ring B to improve the chemical
properties/activity relationship, the 6α-methyl derivate of
CDCA was identified [Pellicciari et al., 2002].With respect
to CDCA, this compound exhibited a tenfold higher activity
as an FXR agonist.This finding indicated the presence
of a hydrophobic pocket in the LBD of FXR corresponding
to the 6α position of BAs. In line with this hypothesis,
6α-alkyl derivates such as 6α-ethyl, n-propyl and n-butyl
derivatives were generated. Among these compounds,
6α-ECDCA (INT-747) was the most potent FXR activator
in a FRET assay. Its activity in this transcriptional assay
was three times higher than CDCA with EC50=99 nM
[Pellicciari et al., 2002]. Other modifications in the ring B
or in the acidic side chain of BAs generated an array of
interesting derivatives for the modulation of FXR activity,
but none was superior to 6α-ECDCA [Pellicciari et al.,
2004].
Natural extracts
Guggulipid, the extract from the gum resin of Commiphora
mukul, is known from traditional Indian medicine for its
hypolipidemic properties consisting of reduced serum
levels of cholesterol, low-density lipoprotein
(LDL)-cholesterol and triglycerides (TGs).The active
principle of guggulipid responsible for these metabolic
effects is the guggulsterone, a mixture of Z- and E-4,
17(20)-pregnadiene-3, 16-dione. From the studies on
guggulsterone, it is now clear that its metabolic effects
are mediated by an array of NRs [Urizar and Moore,
2003].Thus, both Z- and E-guggulsterone interact with
members of the endocrine NR subfamily, including
glucocorticoid receptor (GR), mineralocorticoid receptor
(MR), androgen receptor (AR), progesterone receptor
(PR) and estrogen receptor α (ERα) [Burris et al., 2005],
as well as members of the adopted orphan NR subfamily,
such as pregnane X receptor (PXR) [Brobst et al., 2004]
and FXR. Regarding FXR [Cui et al., 2003; Urizar et al.,
2002;Wu et al., 2002], it has been shown by transfection
experiments that both Z- and E-guggulsterone are unable
to activate this NR, while they can interfere with CDCA
activity.These antagonistic properties were confirmed in
a cell-free coactivator binding assay, where guggulsterone
fails to recruit SRC-1 peptide [Urizar et al., 2002;Wu et
al., 2002]. Nevertheless, guggulsterone was shown to
enhance CDCA and GW4064 (a selective and potent
synthetic FXR agonist) induced BSEP expression [Cui et
al., 2003].Thus, despite its lack of selectivity,
guggulsterone might represent an example of a
gene-selective modulator for FXR.
Other natural extracts contain FXR modulators. Cafestol,
a diterpene isolated from unfiltered coffee brew, has been
shown to have agonistic effects on FXR and PXR in
HepG2 cells, similar to those of CDCA and pregnenolone
16-α carbonitrile (PCN), but it was unable to induce
hepatic FXR target genes in vivo. [Ricketts et al., 2007].
Indeed, the hypercholesterolemic properties of cafestol
are due to its ability to induce the fibroblast growth factor
www.nursa.org  NRS  | 2010 |  Vol. 8 |  DOI: 10.1621/nrs.08005 | Page 7 of 28
Review The bile acid sensor FXR15 (FGF15) in the small intestine, which by repressing
CYP7A1, would induce accumulation of cholesterol in the
body [Nilsson et al., 2007]. Furthermore, stigmasterol, a
soy lipid-derived phytosterol, was able to interfere with
the induction of FXR target genes in HepG2 cells [Carter
et al., 2007]. Finally, the prenylated chalcone
xanthohumol, derived from beer hop, was shown to
reduce serum and hepatic TGs levels in animal models
of diabetes and to induce BSEP expression in hepatoma
cells, suggesting that this molecule may be an FXR
agonist [Nozawa, 2005].
Synthetic ligands
Since BAs do not display strong selectivity for FXR,
scientists were prompted to develop synthetic molecules
with higher affinity and selectivity for this NR. A lead
compound in this field is represented by the TTNPB
compound, a synthetic retinoid with low affinity for FXR
identified in coactivator recruitment assays [Parks et al.,
1999; Zavacki et al., 1997]. Starting from the structure of
the TTNPB, different stilbene derivatives were
synthesized [Love et al., 2002; Maloney et al., 2000].
Among these, GW9047 exhibits good selectivity, but low
affinity for FXR. Modulations of the structure of GW9047
led to GW4064, a selective and potent activator of FXR
(EC50=90 nM) that is still seen as the reference
compound.This synthetic molecule is an FXR agonist
active both in vitro and in vivo, but unfortunately it displays
a limited bioavailability that precludes the possibility of
using it in clinical phases. Starting again from TTNBP,
new modifications on its backbone, to avoid retinoic acid
receptor (RAR) binding, yielded other FXR ligands, such
as AGN29, AGN31 and AGN34 [Dussault et al., 2003].
While AGN29 and AGN31 exhibit agonistic properties for
both FXR and RXR with an EC50=1 µM, AGN34 turned
out to be an FXR and RXR antagonist.The benzopyran
structure was also used as a starting point to generate
FXR agonists and the biaryl cinnamate derivates such
as fexaramine and fexarine resulted as selective and
potent FXR agonists with an EC50=38 nM and EC50=36
nM, respectively [Downes et al., 2003]. Interestingly, gene
expression analysis on primary human hepatocytes
revealed that CDCA, GW4064 and fexaramine activated
FXR target genes differently, suggesting that these FXR
ligands may also act as gene–selective FXR modulators.
This means that they can modulate the expression of
various FXR target genes in different manners, either as
agonists or antagonists.This phenomenon could be
explored to develop FXR modulators in which therapeutic
effects may be separated by unwanted side effects.
Finally, 1,1-biphosphonate esters were shown to activate
FXR with anti-proliferative and hypocholesterolemic
effects [Niesor et al., 2001].
FXR as more than a bile acid sensor
For a long time the physiological effects of BAs were
attributed exclusively to their physico-chemical properties,
which allow them to form fat-solubilizing micelles for the
absorption of lipophilic nutrients. Besides this
well-established role in dietary lipid absorption, in the last
few years it has been revealed that BAs also behave as
signaling molecules (hormones) with systemic endocrine
functions. BAs are in fact ligands for both the
G-protein-coupled receptor (GPCR) TGR5 [Maruyama
et al., 2002;Watanabe et al., 2006] and the nuclear
receptor FXR [Makishima et al., 1999; Parks et al., 1999;
Wang et al., 1999]. Activation of the BA-TGR5 pathway
increases energy expenditure in brown adipose tissue,
which would be beneficial against obesity and insulin
resistance.Through activation of their sensor FXR, BAs
can regulate not only their own homeostasis, but also
cholesterol, TG, and glucose metabolism.Thus, the
BA-regulated transcriptional pathways viaTGR5 and FXR
are promising, novel drug targets for the management of
metabolic diseases such as diabetes, hyperlipidemia,
gallstone disease, cholestasis and enterohepatic tumors.
FXR and bile acid metabolism
BAs are amphipathic molecules synthesized in the liver
from cholesterol by multiple enzymatic steps occurring
in different hepatic cellular compartments, such as the
cytosol, mitochondria, endoplasmic reticulum and
peroxisomes [Russell, 2003].This is the so called
“classical” pathway. How the nascent BAs can shuttle
from one compartment to another is still unknown.
Newly-synthesized BAs are termed primary BAs and
consist of CDCA and CA.The “classical” pathway in
humans leads to an equal amount of CDCA and CA. An
“alternative” pathway is responsible for the production of
oxidized cholesterol molecules that are afterwards
converted predominantly to CDCA in the liver [Chiang,
2002]. Before active secretion of BAs into the canalicular
lumen, primary BAs are conjugated at the C24 carboxyl
group with the amino acids taurine or glycine [Falany et
al., 1994] (Figure 1).This amidation process is very
efficient and it is important to make BAs less hydrophobic,
less cytotoxic, and more readily secretable into bile
[Vessey et al., 1977].Thus, the majority of BAs present
in bile are conjugated.
After a postprandial stimulus, BAs are released from the
gall bladder into the duodenum to promote the absorption
of dietary lipids and lipid soluble vitamins.Then, BAs
travel along the intestine and at the distal ileum the
majority of the BAs (95%) are actively absorbed and
returned to the liver via the portal vein, to be re-secreted
into the bile [Love and Dawson, 1998].This process of
BA recycling is called enterohepatic circulation and is of
extreme importance in terms of energy saving, since BA
biosynthesis is an energetically expensive process
involving more than 15 enzymes [Love and Dawson,
1998]. Only 0.5 g of BAs per day is lost through feces.
This loss is compensated by de novo hepatic synthesis.
During the enterohepatic circulation, conjugated BAs
undergo a de-conjugation process in the distal intestine
by bacterial enzymes.The de-conjugated BAs are then
passively absorbed by enterocytes and returned to the
liver where they will be re-conjugated. Primary BAs
(CDCA and CA) are transformed from anaerobic bacteria
present in the colon to secondary BAs (LCA and DCA,
respectively). Also secondary BAs are passively
re-absorbed from enterocytes to travel back to the liver
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represented by secondary and, for the majority, primary
BAs. LCA, after uptake from the liver, undergoes a double
conjugation, with glycine or taurine first, and then with a
sulfonyl group. In this way, LCA is not efficiently absorbed
in the distal ileum and thereby eliminated with the feces.
This is beneficial since LCA is highly cytotoxic.
BAs are able to repress their own synthesis in a feed-back
way through a synergistic mechanism that involves FXR
in the liver and in the intestine. Under fasting conditions,
BAs are synthesized from cholesterol in the liver and
stored in the gall bladder, ready to be delivered in the
small intestine after a postprandial stimulus.The
rate-limiting step enzyme in the biosynthetic pathway for
the conversion of cholesterol to BAs is the CYP7A1
enzyme, a member of the cytochrome P450 (CYP)
superfamily [Russell, 2003].The orphan nuclear receptor
liver receptor homolog-1 (LRH-1) and liver X receptor
(LXR), an oxysterol sensor, are two important inducers
of CYP7A1 mRNA levels in rodents [Goodwin et al., 2000;
Lee and Moore, 2008; Lehmann et al., 1997; Peet et al.,
1998]. In human, on the other hand, LXR represses
CYP7A1 [Goodwin et al., 2003].The inhibition of CYP7A1
by LXR in human may represent a physiological strategy
to suppress the absorption of dietary cholesterol in the
intestine. BAs are in fact essential for the intestinal
absorption of cholesterol. In line with this hypothesis, a
high-cholesterol diet reduced the expression of CYP7A1
in the liver of African Green monkeys, a species that is
similar to humans in cholesterol and lipoprotein
metabolism [Rudel et al., 1994].Thus, while rodents
would deal with excessive cholesterol by stimulating
CYP7A1 expression in order to increase the catabolism
of cholesterol into BAs, humans may have evolved an
alternative strategy, whereby the absorption of cholesterol
in the intestine is blunted through a decrease in the BA
pool as a result of CYP7A1 repression by LXR.
After feeding, BAs are delivered from the gall bladder in
the duodenum, in order to travel through the enterohepatic
circulation. Activation of FXR in the liver induces the
expression of SHP, which interacts with LRH-1 and
represses its activity [Goodwin et al., 2000; Lee and
Moore, 2008; Lu et al., 2000]. As a consequence,
SHP-LRH-1 interaction results in reduced expression of
CYP7A1 and ultimately BAs synthesis. However, the fact
that BAs are still able to repress CYP7A1 in SHP
knock-out mice indicates that other mechanisms for the
repression of this enzyme are present. Indeed, FXR, in
the murine distal ileum, induces FGF15 (FGF19 is the
human ortholog), a hormone secreted in the portal
circulation that reaches the liver to bind to the fibroblast
growth factor receptor 4 (FGFR4) and repress CYP7A1
via a c-jun N-terminal kinase-dependent pathway [Inagaki
et al., 2005].This mechanism constitutes a crosstalk
between the intestine and liver for the regulation of BA
synthesis.The use of tissue-specific FXR knock-out mice
for the liver and intestine assessed the relative
contribution of hepatic and intestinal FXR in the
repression of CYP7A1 and revealed a more determinant
role for the intestinal FXR [Kim et al., 2007a].
In addition to CYP7A1, another critical cytochrome,
CYP8B1, is involved in the classical pathway of BA
synthesis.This enzyme controls the CA:CDCA ratio by
regulating the synthesis of CA. Just like CYP7A1,
CYP8B1 is repressed by FXR via SHP [Zhang and
Chiang, 2001], but in this case SHP interacts and
represses the ability of the hepatic nuclear factor 4α
(HNF-4α) to induce CYP8B1 expression. Moreover, as
shown in hepatic specific FXR knock-out mice, CYP8B1
expression was repressed, probably via FGF15 [Kim et
al., 2007a]. Notably, hepatic specific knock-out mice for
LRH-1 exhibit reduced expression of CYP8B1, but not of
CYP7A1.These findings suggest that hepatic LRH-1 is
involved in the control of the composition of the BA pool,
but not of its size, which is instead mainly regulated by
the FXR-FGF15 pathway [Lee et al., 2008; Mataki et al.,
2007].
Newly-synthesized BAs are conjugated with taurine or
glycine and then actively secreted in the gall bladder.
FXR regulates both of these critical processes.The
amidation reaction requires an initial activation of BAs to
CoA-thioesters by the BA CoA synthase (BACS).These
activated BAs become the substrate for the
BA-CoA:amino acid N-acetyltransferase (BAAT) enzyme,
which is responsible for the conjugation with glycine or
taurine [Solaas et al., 2000]. Conjugated BAs are potent
natural activators of FXR [Parks et al., 1999], which
positively regulates the expression of BACS and BAAT
[Pircher et al., 2003]. Monoanionic- and
dianionic-conjugated BAs are then actively secreted in
the gall bladder by BSEP and the multidrug related protein
2 (MRP2/ABCC2), respectively.These transporters
belong to the ABC transporter family and are both induced
by FXR at the transcriptional level. Moreover, FXR
activation also induces the expression of the multidrug
protein 3/2 (MDR3/Mdr2, ABCB4/Abcb4), another ABC
transporter involved in the biliary secretion of
phosphatidylcholine [Modica et al., 2009] (Figure 4).The
regulation of these ABC transporters is of critical
importance in order to avoid BA accumulation in the liver
and consequent hepatic injury. Indeed, mutations in the
BSEP and MDR3 proteins are responsible for progressive
familial intrahepatic cholestasis (PFIC) type 2 [Strautnieks
et al., 1998] and 3 [de Vree et al., 1998], respectively (see
below).
After postprandial stimulus, BAs are secreted from the
gall bladder into the small intestine to allow the absorption
of lipophilic nutrients. In the distal ileum, conjugated BAs
are actively reabsorbed in the portal blood, while
unconjugated BAs are only partially absorbed by passive
diffusion. At the enterocyte brush border membrane,
ASBT determines the uptake of BAs [Dawson et al., 2003;
Oelkers et al., 1997]. Once BAs are taken up by ASBT,
they are shuttled from the apical to the basolateral
membrane by IBABP [Gong et al., 1994;Tochtrop et al.,
2004;Toke et al., 2006]. Finally, BAs are secreted in the
portal blood by the heterodimeric organic solute
transporter α/β (OSTα/β [Dawson et al., 2005] (Figure
4).This complex process of active BA absorption is
entirely orchestrated by FXR. Activation of FXR in the
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Review The bile acid sensor FXRFigure 4.  FXR regulates BA metabolism. BAs that recirculate in the enterohepatic system activate hepatic and intestinal FXR to regulate genes
important for BA metabolism. Hepatic FXR 1) represses BA synthesis by reducing CYP7A1 and CYP8B1 expression via SHP and 2) efficiently promotes
BA conjugation (conj-BAs) with taurine or glycine via BACS and BAAT. FXR controls BA secretion in the small intestine by upregulating the expression
of ABC transporters such as MRP2, BSEP and MDR3/Mdr2.When reaching the distal ileum, unconjugated BAs are passively reabsorbed, while
conj-BAs are taken up by ASBT at the luminal membrane, shuttled to the basolateral membrane of the ileal enterocyte by the cytosolic transporter
IBABP, then secreted in the portal blood via the OSTα/β transporter to travel back to the liver and be taken up by the NTCP transporter (repressed by
FXR) and complete the enterohepatic circulation. In addition to regulating genes involved in active BA reabsorption in the distal ileum, activation of
FXR by BAs also induces FGF19/15, a hormone that is secreted in the portal circulation and that signals to the liver through FGFR4 to repress CYP7A1.
During cholestasis, when BAs reach high levels in the liver, FXR also induces OSTα/β to allow BAs to spill over from the liver in the systemic circulation
for their final elimination with urine. Under these pathological conditions FXR also induces phase I (CYP3A4/Cyp3a11) and phase II (SULT2A1 and
UGTB4) reactions to turn BAs into more hydrophilic and less toxic molecules that are efficiently excreted.
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expression of IBABP [Grober et al., 1999; Kok et al., 2003]
and OSTα/β is induced[Landrier et al., 2006; Rao et al.,
2008]. Notably, FXR directly induces IBABP and OSTα/β
expression on the level of their promoters, while the
expression of human ASBT is negatively regulated via
SHP [Neimark et al., 2004].
Similar to the intestine, the active transport system for
BAs absorption regulated by FXR also exists in the bile
duct and kidney. In cholangiocytes, conjugated BAs are
absorbed by ASBT at the canalicular membrane and
secreted by MRP3 and OSTα/β at the basolateral
membrane [Ballatori et al., 2005]. Also in the kidney,
conjugated BAs are absorbed by ASBT, localized at the
apical membrane of proximal renal tubular cells, and then
secreted by OSTα/β from the basolateral membrane in
the systemic circulation [Ballatori et al., 2005; Christie et
al., 1996; Craddock et al., 1998]. Indeed, under normal
conditions, BAs are not excreted into urine.
Although the adrenal gland cortex is not known to be
involved in any aspect of BA metabolism, the expression
of FXR has been detected at high levels also in this tissue
[Forman et al., 1995]. Herein, OSTα and OSTβ were
identified as FXR target genes by in vitro and in vivo
approaches [Lee et al., 2006]. It has been proposed that
when the serum levels of BAs increase, such as in
cholestasis, OSTα and OSTβ would facilitate the uptake
of conjugated BAs into the adrenal glands, resulting in a
feed-forward activation of OSTα and OSTβ by FXR. Since
OSTα and OSTβ form a multifunctional facilitative
transporter, this heterodimer may also export specific
substrates from the adrenal glands. In frog oocytes, OSTα
and OSTβ have been shown to increase the efflux of
dehydroepiandrosterone-3-sulfate [Ballatori et al., 2005].
The human adrenal cortex synthesizes and secretes
dehydroepiandrosterone-3-sulfate, suggesting that also
in humans the OSTα/β heterodimer export conjugated
steroid intermediates from the adrenals glands into the
blood while exchanging conjugated BAs. It is unknown
whether apart from BAs, other endogenous molecules in
the adrenal glands could activate FXR. For example,
androsterone, a metabolite derived from adrenal steroids,
has been reported to activate FXR [Howard et al., 2000].
However, since this activation is relatively weak, it
remains unclear whether androsterone or other steroid
intermediates are of physiological importance for FXR
activation.
BAs are detergent-like molecules.Thus, despite their
beneficial role in solubilizing lipophilic nutrients facilitating
their intestinal absorption, accumulation of high levels of
BAs, especially secondary BAs, can be detrimental.
Notably, BA cytotoxicity increases linearly with the
hydrophobic index [Moschetta et al., 2001]. Indeed, the
order of increasing cytotoxicity is UDCA, CA, CDCA, DCA
and LCA (Figure 1).The cytotoxic effects of BAs have
been demonstrated in FXR knock-out mice which
spontaneously develop hepatic tumors [Kim et al., 2007b;
Yang et al., 2007]. Moreover, accumulation of BAs in the
liver is believed to play a pivotal role in
cholestasis-associated liver damage (see below).Thus,
the concentration of BAs needs to be tightly regulated.
As a BA sensor, FXR controls not only BAs synthesis,
but also their metabolism and clearance.While the first
process is evident under physiological conditions during
the fast-fed state switch, the ability of FXR to induce BAs
biotransformation and elimination is more evident under
pathological conditions (e.g., cholestasis).
The biotransformation process of BAs consists of two
phases occurring mainly in the liver. Phase I involves
oxidation reactions, which generate more polar products.
Then, phase II enzymes are responsible for the
conjugation of phase I products with endogenous
molecules to further increase their water solubility. At this
point, conjugated BAs are polar enough to be easily
eliminated from the body. However, they cannot exit the
liver by passive diffusion.Thus, a phase III of active
secretion is required. In this respect, BAs can be secreted
into the bile by MDR3/Mdr2 and BSEP or into the
systemic circulation by OSTα/β and MRP members for
elimination through urine.This latter process occurs when
secretion of BAs into bile is somehow impaired, as during
cholestasis.
In the liver, CYP3A4/Cyp3a11 is the most important
enzyme involved in phase I reactions. It catalyzes
hydroxylation of BAs at different positions, leading to
3-oxo-, 1-β-, 6-α-, and 22-hydroxy Bas production [Araya
and Wikvall, 1999; Bodin et al., 2005]. Activation of FXR
by GW4064 results in the induction of CYP3A4 in HepG2
cells and Cyp3a11 in wild type mice, but not in FXR
knock-out mice [Gnerre et al., 2004]. Furthermore, FXR
can regulate phase II enzymes involved in glucuronidation
and sulfonation reactions. FXR response elements have
been found in the promoter of the SULT2A1 gene [Song
et al., 2001], whose encoded protein generates
3-α-sulfated BAs.These BAs are low in healthy subjects
[Podesta et al., 1980], while high levels are detected in
cholestatic patients [Takikawa et al., 1983], indicating the
protective role of SULT2A1. However, while FXR
activation fails to induce SULT2A1 expression in HepG2
cells [Fang et al., 2005], the expression of UGT2B4 for
the glucuronidation of 6α-hydroxilated BAs is upregulated
[Barbier et al., 2003]. Interestingly, in colon carcinoma
CaCO2 cells, FXR acts as negative regulator of the
UGT2B7 gene, whose encoded enzyme is involved in
the formation of 3-hydroxy-glucuronidated BAs [Lu et al.,
2005].Thus, FXR seems to control BA glucuronidation
in a tissue- and isoform-specific manner.
Under physiological conditions, bile is the preferential
route used by the liver to secrete BAs. However, under
cholestatic conditions, BAs are also secreted into the
systemic circulation by an alternative basolateral export
system, including OSTα/β, MRP3 and MRP4 [Dawson
et al., 2005]. Under normal conditions, FXR induces the
expression of canalicular BSEP and MRP2, but when
BAs accumulate in the liver at toxic levels, FXR also
induces the expression of basolateral OSTα/β for the
secretion of BAs into the systemic circulation and finally
urinary elimination. In the kidney, BAs are normally
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apical membrane of proximal renal tubular cells and then
secreted by the basolateral membrane OSTα/β into the
systemic circulation [Ballatori et al., 2005; Christie et al.,
1996; Craddock et al., 1998].Thus, under healthy
conditions, BAs are not excreted into urine. Conversely,
during cholestasis, passive glomerular filtration of serum
BAs and repression of ASBT expression [Lee et al., 2001]
account for the loss of BAs through urine. Since FXR
induces the expression of OSTα/β in the kidney [Lee et
al., 2006], the use of a selective antagonist for FXR in
the kidney could have a beneficial effect for patients with
cholestasis. A list of FXR target genes is reported in Table
1.
FXR and cholesterol-triglyceride homeostasis
The downregulation of CYP7A1 via FXR signaling leads
to decreased cholesterol catabolism with consequent
accumulation of hepatic and serum cholesterol.Thus, the
use of an FXR antagonist could represent a promising
approach to decrease cholesterol levels by enhancing
the conversion of cholesterol into BAs. In line with this
idea, as mentioned previously, guggulsterone, a plant
sterol used in Indian herbal medicine, has been shown
to block FXR activity and reduce serum LDL levels, while
increasing high-density lipoprotein (HDL) levels [Urizar
et al., 2002]. Moreover, adenoviral CYP7A1
over-expression in LDL-receptor knock-out mice, which
exhibit high levels of LDL-cholesterol, resulted in reduced
LDL-cholesterol levels [Ratliff et al., 2006].Taken
together, these data suggest that FXR antagonists may
be used for the management of atherosclerosis. However,
the other side of the coin is the role that FXR plays in
intestinal cholesterol absorption. It has been shown that
FXR knock-out mice exhibit increased intestinal
absorption of cholesterol, which indicates a negative
regulatory role for FXR in intestinal cholesterol absorption
[Lambert et al., 2003].The increase in intestinal
cholesterol absorption is probably due to increased
solubilization of cholesterol in the gut via the increased
amount of circulating BAs in these mice. Moreover, FXR
activation seems to contribute to reverse cholesterol
transport, a process that results in the delivery of
cholesterol from peripheral tissues to the liver for biliary
disposal and consequent fecal elimination [Lambert et
al., 2003]. In this metabolic scenario, FXR regulates the
expression of phospholipids transfer protein (PLPT),
responsible for the transfer of phospholipids and
cholesterol from LDL to HDL, hepatic lipoproteins, such
as ApoE, ApoC-I, ApoC-IV, and scavenger receptor B1
(SRB1), which is involved in the hepatic uptake of HDL
and is one of the major actors in the clearance of serum
HDL cholesterol esters (Figure 5).
The BA pool size can also affect TG metabolism. Early
clinical studies suggested a direct relationship between
BA and TG levels, showing that patients with decreased
BA synthesis due to CYP7A1 deficiency presented high
plasmatic levels of TGs [Pullinger et al., 2002]. Moreover,
subjects with monogenic familial hypertriglyceridemia
displayed defects in ileal BA reabsorption [Angelin et al.,
1987]. In line with these evidences, dyslipidemic patients
treated with BA-sequestering resins (e.g., cholestyramine
or cholestipol) presented increased levels of plasma TG
and very-low-density lipoprotein (VLDL) [Angelin et al.,
1987; Beil et al., 1982; Crouse, 1987]. Conversely,
administration of a BA such as CDCA for the management
of hypertriglyceridemia and gallstone disease resulted in
decreased TG levels [Angelin et al., 1987; Bateson et al.,
1978; Bell et al., 1973].The ability of BAs to act as
hypotriglyceridemic agents has also been confirmed in
animal models. In this respect, KK-A(y) mice, an animal
model of hypertrigliceridemia, exhibit reduced TG serum
levels, hepatic TG accumulation and VLDL secretion after
treatment with CA [Watanabe et al., 2004].
Following the discovery that FXR is a transcriptional
mediator of the physiological effects of BA, it was
speculated that the activation of FXR by synthetic ligands
could be exploited to modulate TG metabolism.Thus,
mice and rats treated with GW4064 showed reduced
plasma TG levels [Claudel et al., 2003; Ma et al., 2006;
Maloney et al., 2000; Zhang et al., 2006a]. Interestingly,
administration of GW4064 was also able to improve
hypertriglyceridemia in ob/ob and db/db mice, two animal
models of insulin resistance [Cariou et al., 2005; Zhang
et al., 2006a]. Moreover, FXR agonists reduced free fatty
acids (FFA) levels in insulin-resistant rodents [Bilz et al.,
2006; Zhang et al., 2006a].The important role of FXR in
regulating TG homeostasis has been highlighted in FXR
knock-out mice which exhibit a lipid profile characterized
by high levels of serum TGs and increased hepatic
synthesis of VLDL [Sinal et al., 2000].
FXR controls TG metabolism by regulating hepatic de
novo lipogenesis and triglyceride clearance. Upon
activation by BA or synthetic ligands, FXR downregulates
the expression of SREBP-1c [Watanabe et al., 2004], a
transcription factor that plays a critical role in stimulating
fatty acid synthesis and lipogenesis by inducing the
expression of key enzymes such as the fatty acid
synthase (FAS), acetyl-CoA synthase (AceCS),
acetyl-CoA (ACC) and glycerol-3-phosphate (GPAT)
[Horton et al., 2002] (Figure 5).This metabolic scenario
has been elucidated in a mouse model of obesity and
type 2 diabetes, the KK-A(y) mouse [Watanabe et al.,
2004].When fed with a natural (CA) or synthetic
(GW4064) ligand for FXR, these mice exhibit a significant
reduction in hepatic and serum TG levels, and VLDL
secretion as a consequence of the induced expression
of SHP via FXR. By interfering with LRH1, SHP is able
to blunt the ability of LXR to induce SREBP-1c
expression. Notably, insulin induces SREBP-1c
expression and maturation [Foretz et al., 1999;
Shimomura et al., 1999], but also LXR [Steffensen and
Gustafsson, 2004;Tobin et al., 2002].Thus, while the
LXR-LRH1- SREBP-1c cascade plays a key role in
inducing lipogenesis, on the other hand the
FXR-SHP-SREBP-1c cascade plays a crucial role in
repressing lipogenesis.The central role of SHP in
inhibiting SREBP-1c was confirmed by the combined use
of natural (CA) or synthetic (GW4064) FXR agonists and
SHP knock-out mice [Watanabe et al., 2004]. In these
mice, activation of FXR did not result in lower TG levels.
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Interestingly, the observation that FXR knock-out mice
have normal or even reduced SREBP-1c mRNA levels
[Duran-Sandoval et al., 2004; Zhang et al., 2004]
suggests that FXR-independent mechanisms also must
play an important role. However, since FXR knock-out
mice exhibit increased serum and hepatic TG levels along
with increased production of VLDL, FXR activation may
control de novo lipogenesis via SREBP-1c-dependent
and -independent mechanisms.
In addition to the reduction of de novo lipogenesis, FXR
activation may also modulate TG clearance.This
additional TG-lowering effect of FXR is explained at the
molecular level by the induction of key genes, such as
Apo-C-II [Kast et al., 2001], an activator of lipoprotein
lipase (LPL) activity responsible for VLDL-TG hydrolysis,
and the VLDL receptor, in both human and mouse livers,
which enhances the clearance of TG-rich lipoproteins
(Figure 5). Activation of FXR has also been shown to
induce the in vitro expression of syndecan-1 [Anisfeld et
al., 2003], a transmembrane herpain sulfate proteoglycan
responsible for the clearance of remnant particles. Also,
activation of FXR represses the expression of Apo-C-III
[Claudel et al., 2003] and ANGPTL3 [Watanabe et al.,
2004], two PLP inhibitors. Finally, an FXR agonist may
induce the expression of peroxisome proliferator activated
receptor α (PPARα) and in turn its target gene pyruvate
dehydrogenase kinase-4 (PDK-4), to promote fatty acid
oxidation [Pineda Torra et al., 2003; Savkur et al., 2005a]
(Figure 5).Taken together, these studies propose FXR
as a pharmacological target for the management of
hypertriglyceridemia and fatty liver disease, two common
features of the metabolic syndrome in humans.
In summary, the use of FXR agonists would be beneficial
for the reduction of TG levels, but detrimental in regard
to the induction of LDL-cholesterol and reduction of
HDL-cholesterol levels. Instead, the use of FXR
antagonists would be beneficial to reduce LDL-cholesterol
and increase HDL-cholesterol levels, but disadvantageous
because of the increased TG levels. Indeed, the benefit
of FXR antagonists or agonists in diseases such as
atherosclerosis, hypercholesterolemia and
hypertriglyceridemia, remains to be established. For the
future, the identification of specific FXR isoforms linked
to a specific lipid-metabolic pathway would be extremely
helpful for the design of specific FXR (ant-)agonists
targeting the desired pathway without undesirable side
effects.
FXR and glucose metabolism
A physiological role for FXR in glucose metabolism has
emerged in the last few years by the discoveries of the
effects of FXR on gluconeogenesis, glycogen synthesis,
and insulin sensitivity.The link between FXR and glucose
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Review The bile acid sensor FXRFigure 5.  FXR regulates lipid metabolism. By repressing CYP7A1 and CYP8B1 via SHP and FGF19, FXR activation may result in hepatic
cholesterol accumulation. In the liver, FXR activation results in increased expression of PLPT for the transfer of phospholipids and cholesterol from
LDL to HDL, SRB1 for the hepatic uptake of HDL and lipoproteins ApoE, ApoC-I and ApoC-IV. Activation of FXR also leads to the repression of hepatic
lipogenesis by reducing the expression of SREBP1-c in a SHP-dependent manner. SREBP1-c induces the expression of key genes for fatty acids
synthesis and lipogenesis such as AceCS, FAS, ACC, and GPAT. By increasing the expression of PPARα, FXR also promotes FFA catabolism via
β-oxidation. By repressing the expression of MTP, an enzyme that controls VLDL assembly, FXR reduces VLDL production. Activation of FXR increases
TG clearance by promoting PLP activity, via induction of ApoC-II, and by upregulating the expression of VLDL-R and syndecan-1 for the hepatic uptake
of LDL and IDL (remnants). Activation of FXR also reduces TG clearance by decreasing the expression of ApoC-III and ANGPTL3, two PLP inhibitors.
homeostasis has been highlighted by several studies
showing that BAs profile is altered by diabetes [Staels
and Kuipers, 2007].The BA pool size is markedly
increased in rat models of diabetes, suggesting that
insulin may affect BA synthesis and secretion [Hassan
et al., 1980; Nervi et al., 1974]. Indeed, insulin
administration was able to restore a normal BA pool size
in experimental models of diabetes [Nervi et al., 1978;
van Waarde et al., 2002]. Moreover, liver-specific insulin
receptor knock-out mice showed increased bile volume,
suggesting a larger BA pool size [Michael et al., 2000].
Taken together, these observations indicate that the
negative feedback mechanism repressing BA synthesis
is impaired in diabetes. Concurrently, in rat models of
diabetes, hepatic FXR expression is decreased and
CYP7A1 consequently induced.Thereby, BA pool size
is increased, but notably after insulin administration FXR
and CYP7A1 gene expression is restored
[Duran-Sandoval et al., 2004]. Moreover, BA synthesis
is reduced in vitro in rat hepatocytes treated with a
physiological concentration of insulin, due to the reduced
expression of CYP7A1 [Twisk et al., 1995].
While insulin regulates FXR expression, FXR has an
impact on insulin sensitivity. Compared to wild type mice,
FXR knock-out mice exhibit impaired glucose tolerance
and insulin sensitivity [Cariou et al., 2006; Ma et al., 2006;
Zhang et al., 2006a]. Conversely, mice treated with
natural (CA) and synthetic (GW4064) FXR ligands, or
infected with an adenovirus expressing a
constitutively-active form of FXR (VP16-FXR), showed a
marked reduction in plasma glucose levels and improved
insulin sensitivity [Cariou et al., 2006; Ma et al., 2006;
Zhang et al., 2006a].These effects were seen in mouse
models of diabetes such as db/db, ob/ob and KK-A(y)
mice. Since FXR is not expressed in skeletal muscle and
very low levels are detected in white adipose tissue, it is
conceivable that the molecular mechanisms behind the
peripheral insulin sensitizing effect of FXR could be
indirect. FXR knock-out mice exhibit elevated circulating
FFA, as well as increased content of TGs and FFA in the
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is believed that this phenomenon known as “lipotoxicity”
could impair insulin signaling at the peripheral level
[Savage et al., 2007] (Figure 6). Moreover, a similar
mechanism could operate in the liver and pancreas, in
the latter case reducing the secretion of insulin. Activation
of FXR would reduce the “lipotoxicity” phenomenon by
decreasing the levels of TGs and FFA (see FXR and TG
metabolism) and restoring insulin secretion and sensitivity.
Indeed, in vivo studies on FXR knock-out mice
demonstrate a lipoatrophic phenotype that would be
responsible for interfering with insulin sensitivity [Cariou
et al., 2006; Rizzo et al., 2006]. Also, it has recently been
shown that treatment of adipocyte-like 3T3-L1 cells with
FGF19 results in increased glucose uptake [Kurosu et
al., 2007]. Moreover, resistance to insulin desensitization
was observed in FGF19 transgenic mice. However, the
FGF19 effects are less important in white adipose tissue
than in the liver, suggesting that the extra-hepatic activity
of FGF19 was due to supra-physiological concentrations
[Tomlinson et al., 2002]. It is conceivable that an increase
in fatty acid oxidation, as a consequence of the inhibition
of hepatic acetyl CoA carboxylase 2 (ACC2) and steaoryl-
CoA desaturase-1 (SCD-1), would account for the
reduced hepatic TG levels and the following improved
insulin sensitivity. Overall, these studies suggest that the
FXR-dependent insulin-sensitizing effects may, to some
extent, be mediated by FGF19. In order to better dissect
this scenario, studies of tissue-specific FXR knock-out
mice are required to demonstrate the relative contribution
of the liver, intestine and white adipose tissue in insulin
sensitivity. On the other hand, one cannot exclude that
FXR activation also might lead to increased synthesis or
secretion of insulin by the pancreatic cells, and the higher
circulating insulin levels could somewhat counteract the
insulin-resistant phenotype of the diabetic animal models.
Another goal in diabetes management, to improve insulin
sensitivity, is to limit hepatic output of glucose by reducing
gluconeogenesis and glycogenolysis [Moller, 2001]. In
this respect, FXR would be a suitable target since it has
been demonstrated that the activation of FXR may reduce
hepatic gluconeogenesis and induce glycogen synthesis
[Cariou et al., 2006; Ma et al., 2006; Zhang et al., 2006a].
Since VP16-FXR over-expression in the liver confirmed
the results obtained by pharmacological treatment known
to activate FXR in the liver, intestine and kidney, a key
role for hepatic FXR in glucose homeostasis, rather than
extra-hepatic FXR, is inferred. In the liver of mouse
models of diabetes, activation of FXR represses the
expression of phosphoenoyl-pyruvate carboxykinase
(PEPCK), glucose-6-phosphatase (G6Pase) and fructose
1,6-bis phosphatase (FBP1), three rate-limiting enzymes
in the glucogenetic process [Ma et al., 2006; Zhang et
al., 2006a] (Figure 6). At the molecular level, these
findings are explained by the repressive effects of the
FXR-SHP pathway on transcription.The expression of
PEPCK, G6Pase and FBP1 is positively-regulated by
different transcription factors and coactivators.
Specifically, HNF4α, GR, forkhead transcription factor
Foxo1 and PGC1α cooperate to induce the expression
of these three enzymes in the fasting state. Activation of
FXR by CA [Ma et al., 2006] or GW4064 [Zhang et al.,
2006a] induces the expression of SHP, which in turn
disrupts the interaction of PGC1α with GR, HNF4α and
Foxo1 with a final decrease of gluconeogenesis in db/db
and KK-A(y) diabetic mouse models, but not in FXR
knock-out mice [Borgius et al., 2002;Yamagata et al.,
2004]. In support of the concept that BAs repress
gluconeogenesis via the FXR-SHP pathway,
over-expression of SHP reduces gluconeogenic gene
expression. Besides the direct role of SHP in reducing
the mRNA levels of these three enzymes, it is also
possible that FXR may act indirectly by increasing hepatic
insulin sensitivity and reducing serum FFA levels. Notably,
in contrast with the diabetic mice, studies on wild type
mice with FXR agonists showed stimulation [Stayrook et
al., 2005; Zhang et al., 2006a] or repression [De Fabiani
et al., 2003; Ma et al., 2006;Yamagata et al., 2004] of
PEPCK, paralleled by decreased or unchanged glucose
levels [Ma et al., 2006; Stayrook et al., 2005; Zhang et
al., 2006a].The explanation for these discrepancies
remains to be determined. Moreover, the in vitro use of
GW4064 resulted in induction rather than suppression of
PEPCK [Stayrook et al., 2005]. In line with this evidence,
administration of GW4064 to fed mice also resulted in
the upregulation of PEPCK.These differences in the
literature may be due to the fast-feeding regulation of this
important FXR-driven scenario. Parallel to G6Pase
reduced expression, activation of FXR induces glycogen
synthesis in the liver of diabetic db/db mice as a
consequence of increased phosphorylation of glycogen
synthase kinase 3α (GSK3α), a critical regulator of
glycogen synthase [Zhang et al., 2006a] (Figure 6). In
accordance with this finding, FXR knock-out mice exhibit
reduced hepatic glycogen content [Cariou et al., 2005].
Despite the discrepancies in the literature regarding the
role of FXR in glucose metabolism, FXR agonists may
be useful for the management of type 2 diabetes.
Moreover, the observation that activation of FXR results
in insulin substrate receptor 1 (IRS-1) phosphorylation in
the liver and adipose tissue suggests a potential
application of FXR ligands for the management of patients
with insulin resistance [Ma et al., 2006]. Studies on human
patients are ongoing and the results will shed light on
FXR as an anti-diabetic target.
A list of FXR target genes involved in glucose metabolism
is reported in Table 1.
FXR and disease
Cholestasis
Cholestasis is a pathological condition characterized by
impairment or reduction of bile flow. It results from defects
in the process of bile formation in hepatocytes or
cholangiocytes (intrahepatic cholestasis), or alternatively
from physical obstructions in bile ducts due to tumors or
stones (extrahepatic cholestasis). As a consequence,
accumulation of potentially toxic biliary constituents leads
to initial hepatic fibrosis and inflammation that may result
in cirrhosis, cancer and finally liver failure. Alterations in
the bile formation process can derive from inflammation,
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tissues (skeletal muscle and adipose tissue) by reducing the levels of TGs and FFA. High levels of circulating TGs and FFA can impair insulin signaling
and reduce pancreatic insulin secretion, a phenomenon known as “lipotoxicity”.The increased insulin sensitivity due to the attenuation of the “lipotoxicity”
phenomenon following FXR activation, results in increased glycogen synthesis and reduced gluconeogenesis, two desirable events for the management
of diabetes. Activation of FXR induces GSKα expression to promote glycogen synthesis and repress in a SHP-dependent way three key enzymes
involved in gluconeogenesis such as PEPCK, FBP1 and G6Pase, but an induction of PEPCK after FXR agonist treatment has been also reported. In
this scenario of glucose metabolism regulated by FXR, glucose and insulin increase the expression of FXR.
drug administration, pregnancy or hereditary defects in
the transport systems needed for bile formation/secretion.
In the latter case, PFIC1, also termed Byler disease,
affects patients with mutations in FIC1, a putative
aminophospholipid transferase on the hepatocyte
canalicular membrane, while mutations in BSEP and
MDR3 are responsible for PFIC2 and PFIC3 diseases
[Bull et al., 1998; de Vree et al., 1998; Strautnieks et al.,
1998]. Other forms of cholestasis include primary biliary
cirrhosis (PBC) and primary sclerosis cholangitis (PSC),
two progressive liver disorders characterized by bile duct
proliferation associated with bile flow impairment and liver
damage [Bergasa et al., 2004; Levy and Lindor, 2006].
Irrespective of the etiology of cholestasis, accumulation
of toxic hydrophobic BAs in the liver is thought to play a
key role in cholestasis-associated liver damage.Thus
far, the use of UDCA, a polar BA that reduces the
hydrophobicity and toxicity of the BA pool, is the only
pharmacological intervention recognized for the
management of cholestasis [Paumgartner and Beuers,
2002]. However, while endoscopy and surgery are
effective therapies for most of the patients with obstructive
cholestasis, therapeutic approaches based on UDCA for
non-obstructive cholestasis, especially those with a
genetic background, remain mostly ineffective [Goulis et
al., 1999; Paumgartner and Beuers, 2002].Therapies
aiming at reducing the size and hydrophobic index of the
BA pool during cholestasis are still missing.
The discovery that FXR is the master regulator of BA
homeostasis makes this NR a suitable pharmacological
target for the management of cholestasis. Activation of
FXR could reduce BA synthesis by repressing CYP7A1
and CYP8B1 expression, decrease hepatic BA uptake
by downregulating the Na
+/taurocholate cotransporting
polypeptide (NTCP) and increase the expression of MDR3
and BSEP for the secretion of BAs from the liver into bile
(Figure 4).The final result would be a reduced hepatic
BA overload. It is noteworthy that in those forms of
cholestasis that are characterized by compromised activity
of BSEP and MDR3 (as in PFIC2 and PFIC3,
respectively), BAs can spill over from the liver at the
basolateral membrane through transporters such as
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FXR can induce phase I and phase II reactions to make
BAs more hydrophilic and ready for excretion through
urine. In line with the important role that FXR plays to
keep BA levels under control, FXR knock-out mice
present a phenotype similar to Byler disease, a hereditary
form of cholestasis with reduced FXR expression.
Furthermore, four different heterozygous functional
variants of FXR (-1>g, M1V, W80R, M173T) were found
in patients affected by intrahepatic cholestasis of
pregnancy (ICP), a pathological condition occurring in
1/200 pregnancies in Caucasian women, that can lead
to intrauterine fetal death [Heinonen and Kirkinen, 1999;
Rioseco et al., 1994]. Characterization of these variants
displayed functional defects in either translational
efficiency or activity in three of the four variants (-1>g,
M1V, M173T) [Van Mil et al., 2007].
The protective role of FXR activation in cholestasis has
been investigated in mouse and rat models for this
disease.Treatment with GW4064 reduced bile duct
proliferation, inflammation and liver damage induced by
bile duct ligation (BDL) and α-naphtylisothiocyanate
(ANIT), the two experimental setups generally used to
induce cholestasis. Moreover, both GW4064 and
6α-ECDCA were able to protect rats from ethinyl
estradiol-induced cholestasis.The mechanism proposed
for the protective effect of FXR observed in these studies
focused only on the liver and was ascribed to the reduced
expression of CYP7A1 and NTCP, and the induced
expression of MRP2 and BSEP. However, since the
reduced BA pool size, as a consequence of the decreased
expression of CYP7A1, could play the main role in the
protection against cholestasis after FXR activation, and
since it was recently shown that the intestinal FXR-FGF15
pathway plays a crucial role in repressing CYP7A1
expression, the relative contribution of hepatic and
intestinal FXR activation against cholestasis should be
investigated by the use of tissue-specific FXR knock-out
mice.
In contrast to the studies reported above, suggesting a
protective role of FXR activation against cholestasis, other
evidences suggest that FXR inhibition also may have a
protective role in cholestasis [Marschall et al., 2006;
Stedman et al., 2006]. FXR knock-out mice were shown
to be protected from liver injury caused by BDL.These
mice adapt to BDL by a significant increased expression
of MRP4, suggesting that FXR may negatively regulate
this hepatic basolateral transporter.The induction of
MRP4 expression represents an important adaptive
mechanism against cholestasis to protect the liver from
accumulation of BAs during cholestasis, by stimulating
their efflux into the systemic circulation for final renal
excretion.Thus, MRP4 knock-out mice are susceptible
to cholestatic-induced liver damage [Mennone et al.,
2006]. Moreover, subjects with PFIC [Jansen et al., 2001]
and mice, as well as rats, present a marked upregulation
of MRP4 expression after BDL [Denk et al., 2004;
Mennone et al., 2006]. Overall, these findings imply that
inhibition of hepatic FXR may represent an important
adaptive mechanism observed in cholestasis.
In summary, FXR activation reduces the BA pool size,
the most important determinant in cholestasis, by
downregulating CYP7A1 expression via a synergistic
mechanism that involves hepatic and intestinal FXR.
However, hepatic FXR activation may also reduce the
expression of basolateral transporters, such as MRP4,
which are required for BA secretion into systemic
circulation and consequent renal elimination. For these
reasons, a selective activation of intestinal FXR would
be more beneficial than a systemic activation of FXR.
Through this selective activation, the total BA pool would
be reduced by the FXR-FGF15/19 pathway, while the
adaptive hepatic response would normally function.
Another option would be the generation of drugs that
would act as gene selective modulators for FXR by
reducing the expression of CYP7A1, inducing the
expression of BSEP, MDR3, OSTα/β and MRP4, and
repressing the activity of FXR in the kidney to reduce BA
uptake at this level. Finally, it is worth mentioning that the
mouse models of cholestasis used so far are not
completely representative of the human situation. It would
be more relevant to investigate the role of FXR activation
in genetic mouse models of cholestasis with the same
mutations as those observed in humans (e.g., PFICs).
Cholesterol gallstone disease
The correct ratio of biliary BAs, phospholipids and
cholesterol is of crucial importance for maintaining
cholesterol in solution in the bile and preventing the
precipitation of cholesterol crystals, the first step in
cholesterol gallstone formation [Lo Sasso et al., 2008;
Portincasa et al., 2006]. Bile with a high BA and
phospholipid versus cholesterol ratio protects from
gallstone formation, while high cholesterol versus BA and
phospholipid ratio predisposes to cholesterol gallstone
disease (CGD).Thus, the protective role of FXR against
CGD was suggested. Indeed, FXR knock-out mice are
more susceptible to cholesterol gallstone formation than
wild type mice, after feeding them with a lithogenic diet.
This higher susceptibility is a consequence of lower BA
and phospholipid versus cholesterol ratio in bile
[Moschetta et al., 2004]. At the molecular level, decreased
expression of BSEP and Mdr2 were observed in FXR
knock-out mice, while the expression of biliary cholesterol
transporters, such as ABCG5 and ABCG8, was
unchanged. Moreover, treatment with GW4064 of C57L
mice, which are susceptible to CGD when fed with a
lithogenic diet, prevents gallstone formation [Moschetta
et al., 2004]. Compared to vehicle-treated mice,
GW4064-treated mice showed an increased expression
of BSEP and Mdr2 that was coupled with a higher biliary
content of BAs and phospholipids and a consequent
reduced cholesterol saturation index.Thus, activation of
FXR is crucial for maintaining proper solubilization of
cholesterol into bile, by inducing the expression of BSEP
and MDR3/Mdr2, and FXR agonists may be useful for
the prevention or management of CGD. However,
activation of FXR inhibits BA synthesis by reducing
CYP7A1 expression, resulting in a decreased BA pool
size, the most important determinant of the secretory rate
of BAs.This would result in less BA content in bile,
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formation. Notably, in the mouse models of CGD, the use
of the lithogenic diet, containing 0.5% of CA, is a must to
induce gallstone formation [Tepperman et al., 1964].The
CA in the lithogenic diet increases the BA pool size and
compensates for the reduced expression of CYP7A1 after
GW4064 treatment.This would account for the protective
effects obtained with GW4064 in this animal model of
CGD despite the downregulation of CYP7A1.The
situation is quite different in patients with CGD.These
subjects may be treated with FXR agonists in association
with hydrophilic BAs (e.g., UDCA, a prescription drug in
CGD), with the synergistic effect of inducing BA and
phospholipid secretion into bile while maintaining BA pool
size and decreasing total BA hydrophobicity index.
Intestinal diseases
The levels of BAs in the intestine have to be tightly
regulated. Reduced intestinal BA concentration, due to
bile flow obstruction, results in bacterial overgrowth and
translocation across the mucosal barrier with possible
systemic infection. On the other hand, an excessive level
of BAs in the intestine, resulting from defects in BA
reabsorption, results in chronic diarrhea, inflammatory
bowel disease and promotion of intestinal tumorigenesis.
BAs have long been known to have surfactant properties
responsible for keeping intestinal bacterial proliferation
under control. Moreover, it has been recently shown that
part of the antibacterial activity of BAs is mediated by
FXR [Inagaki et al., 2006]. FXR knock-out mice exhibit
hyper-proliferation of intestinal bacteria and evidence of
a compromised epithelial barrier with consequent
inflammation due to bacteria infiltration and recruitment
of activated macrophages/neutrophils [Inagaki et al.,
2006; Modica et al., 2008]. Notably, treatment of wild type
mice with GW4064 was able to reverse both intestinal
bacterial overgrowth and the integrity of the epithelial
barrier caused by BDL [Inagaki et al., 2006].These
protective effects of FXR activation were seen in neither
sham operated nor BDL FXR knock-out mice. Under
physiological conditions, activation of intestinal FXR by
BAs is important for controlling bacterial proliferation and
maintaining the integrity of the epithelial barrier. At the
transcriptional level, FXR induces the expression of genes
involved in intestinal mucosa defense such as interleukin
18 (IL18), inducible nitric oxide synthase (iNOS) and
carbonic anhydrase 12 (CAR12) (Table 1). Moreover,
induction of FGF15 by FXR could also protect the
intestine. FGF15 knock-out mice present an altered
intestinal morphology, suggesting that some of the
functions of FXR in the intestine are mediated by FGF15
[Inagaki et al., 2005].The relevance of this scenario for
the regulation of intestinal inflammatory disorders is an
active research field for several laboratories.
In humans, reduced intestinal BA reabsorption and
increased fecal BA excretion contributes to chronic
diarrhea occurring in different clinical contexts, including
Crohn’s disease, post-gastrectomy syndrome, and short
bowel syndrome. In most cases, the molecular
mechanisms underlying the disruption of the
enterohepatic circulation are unknown. However,
mutations in the ASBT gene is one cause for intestinal
BA malabsorption in humans [Oelkers et al., 1997].
Indeed, ASBT knock-out mice recapitulate key aspects
of BA malabsorption in humans [Dawson et al., 2003].
This mouse model exhibits impaired FXR activity in both
intestine and liver.Thus, FGF15 and SHP expression is
reduced with consequent upregulation of CYP7A1
expression that results in a vicious cycle of increased BA
production. Currently, a major drug against BA
malabsorption is cholestyramine, a resin that,
sequestering BAs in the intestine, protects the bowel from
exposure to the increased levels of colonic BAs. However,
cholestyramine is unpalatable and exhibits adverse side
effects including constipation, vitamin deficiency
[Hathcock, 1985], and hypertrigliceridemia [Crouse, 1987].
In addition, by sequestering BAs in the intestine, treatment
with cholestyramine could result in increased BA
production by interrupting the normal feedback repression
of hepatic BA synthesis. Using ASBT knock-out mice, it
has been shown that GW4064-dependent FXR
reactivation results in reduced BA pool size and fecal
excretion as a consequence of the decreased CYP7A1
expression via hepatic SHP and intestinal FGF15.This
finding may be of important therapeutic potential in
diseases associated with BA malabsorption. Moreover,
FXR agonists decrease circulating TG levels, protecting
against one of the major side effects of cholestyramine
and other resins. Indeed, by breaking the cycle of
increased BA synthesis in BA malabsorption-related
diseases, the use of synthetic FXR ligands or a hormonal
therapy based on FGF19 would be beneficial for patients
with either temporary or long-term interruption of
enterohepatic circulation due to BA malabsorption.
Liver regeneration and tumorigenesis
It has been known for a long time that BAs are able to
induce hepatocyte proliferation and liver regeneration
[Barone et al., 1996]. Conversely, blocking the
enterohepatic circulation of BAs results in the inhibition
of liver regeneration [Ueda et al., 2002]. Recently, a key
role for FXR in mediating BA-induced liver regeneration
has been suggested. Administration of a diet containing
0.2% CA stimulated liver regeneration in partial
hepatectomized mice, while a diet containing the BA
sequestrant resin cholestyramine delayed liver
regeneration [Huang et al., 2006]. In line with these
observations, FXR knock-out mice presented impaired
liver regeneration ability [Huang et al., 2006].This data
suggests a direct involvement of FXR in BA-induced liver
regeneration. However, unlike BAs that have
FXR-dependent and -independent activities, the use of
a selective synthetic ligand for FXR such as GW4064
was unable to induce the liver regeneration process
[Huang et al., 2006]. It is possible that a normal BA pool
size can blunt the hepatic proliferative effect of FXR
activation by a synthetic ligand.To investigate the hepatic
proliferative effects of synthetic FXR agonists, a mouse
model of partial hepatectomy with a decreased BA pool
size (such as during cholestyramine treatment) should
be used.The importance of BAs and FXR in hepatic
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hepatocellular carcinoma (HCC).
HCC is the primary liver tumor and is one of the most
common forms of cancer in the world.The etiology of this
disease mainly includes hepatitis B and C infections,
alcoholic and non-alcoholic fatty liver diseases, chemicals
and, to a lesser extent, genetic defects such as
hematochromatosis and α-1-antitrypsin deficiency
[Deugnier and Turlin, 2001; Propst et al., 1994].
Regardless of the liver cancer etiology, irregular liver
regeneration represents a general mechanism of
hepatocarcinogenesis [Shibata et al., 1998; Ueno et al.,
2001]. Common pathological changes in the development
of liver tumors consist of inflammation and chronic liver
injury, which can lead to a continuous proliferation of
hepatocytes at a higher rate than normal liver cells. In
contrast to the normal liver regeneration, a process where
the liver resumes its normal size after an injury and stops
proliferating within a short period of time, the
hepatocarcinoma process consists of an uncontrolled
proliferation that does not stop because of chronic injury.
Recently it has been shown that BAs can also promote
liver tumorigenesis. A BA-supplied diet in a Hepatitis B
Virus (HBV) transgenic mouse model was able to promote
hepatic tumors, an effect also observed in Mdr2 knock-out
mice [Barone et al., 2003; Katzenellenbogen et al., 2006;
Mauad et al., 1994]. Moreover, a CA diet has been shown
to promote chemical-induced hepatocarcinogenesis [Yang
et al., 2007]. Since FXR tightly regulates BA
concentration, thereby protecting from detrimental effects
of BA toxicity, a role for FXR in HCC can be supposed.
In accordance with this, FXR knock-out mice, which have
chronic high levels of circulating BAs, spontaneously
develop HCC between 12-15 months of age [Kim et al.,
2007b;Yang et al., 2007].These findings suggest a
protective role of FXR during the life span against
hepatocarcinoma development. However, whether and
how FXR directly suppresses liver tumorigenesis remains
to be established. It is likely that FXR acts as a metabolic
oncosuppressor by keeping BA concentration under
physiological levels or by reducing the toxic properties of
BAs.These levels of BAs would otherwise increase to
toxic levels in the absence of FXR and induce chronic
hepatic injury, ultimately resulting in liver tumorigenesis.
However, it is interesting to note that FXR is required for
both liver regeneration and protection against hepatic
tumorigenesis, suggesting an intrinsic link between these
two cellular processes.This link should be exploited to
find new therapies for the management of HCC.
Intestinal tumorigenesis
The role of FXR in carcinogenesis is not restricted only
to the liver. Recent studies have highlighted an
oncosuppressive role for FXR in intestinal tumorigenesis
[Maran et al., 2009; Modica et al., 2008;Yang et al.,
2007]. Colorectal cancer (CRC) is a primary intestinal
tumor, and is nowadays a leading cause of cancer-related
death in the Western world [Arnold et al., 2005; Potter,
1999]. CRC is a long multistep process that arises from
a combination of genetic and environmental causes.
Mutations in the tumor suppressor adenomatous
polyposis coli (APC) gene are detectable in dysplastic
aberrant crypt foci (ACFs), the smallest neoplastic lesion
in the CRC development process, and are believed to be
the primum movens for the initiation of the majority of
sporadic and hereditary forms of CRC.These
observations make APC the gatekeeper in CRC
development. However, patients with APC mutations do
not necessarily develop CRC; additional mutations are
required in order to develop tumors and in this respect
environmental factors are likely to have an important
contribution [Kinzler and Vogelstein, 1996].
Epidemiological studies indicate that a high fat/cholesterol
diet may increase the susceptibility to CRC, while a low
fat/high fiber diet can protect against CRC [Willett, 2001].
One possible mechanism by which a long term
“Western-style” diet may contribute to CRC is through a
chronic exposure to toxic high levels of BAs derived from
excessive cholesterol catabolism. Consistent with this
hypothesis, animal studies link BAs, especially secondary
BAs, to CRC, and human epidemiological studies indicate
that the tumor promoting activity of a “Western-style” diet
is accompanied by an increase in colonic BA
concentrations with higher levels in the feces [Bianchini
et al., 1989; Reddy et al., 1978]. Furthermore,
cholecystectomy, which leads to an increased intestinal
exposure to BAs, has been suggested as a predisposing
factor for the development of CRC [Giovannucci et al.,
1993; Lagergren et al., 2001].
Although BAs are tumor-promoting agents, FXR is not
involved in mediating their tumorigenic effects. On the
contrary, FXR expression is reduced in CRC after an APC
mutation, as in APC 
min/+ mice [Maran et al., 2009; Modica
et al., 2008], a mutant murine lineage carrying a nonsense
mutation of the APC gene [Moser et al., 1990], and
patients with familial adenomatous polyposis (FAP)
[Modica et al., 2008], a hereditary form of colon cancer
which just like APC 
min/+ mice possess inactivating
nonsense mutations in the APC gene [Kinzler et al., 1991;
Powell et al., 1993]. Moreover, crossing FXR knock-out
mice with APC 
min/+ resulted in increased number and size
of intestinal tumors and earlier mortality than APC 
min/+
mice [Maran et al., 2009; Modica et al., 2008]. Finally, as
in the APC 
min/+ model, the lack of FXR was able to
promote tumorigenesis in a chemical model of colon
carcinogenesis associated with chronic colitis [Maran et
al., 2009; Modica et al., 2008; Popivanova et al., 2008].
It is worth noting that, unlike liver tumorigenesis, the
susceptibility of FXR knock-out mice to intestinal
tumorigenesis does not relate to the elevated levels of
BAs, as shown by treatment with cholestyramine,
indicating that the loss of FXR, and not merely elevated
BA concentrations, promotes intestinal tumors. It has
been demonstrated that activated macrophages further
promote WNT/β-CATENIN signaling and intestinal tumor
development in APC 
min/+ mice through the tumor necrosis
factor α (TNFα) [Oguma et al., 2008]. Moreover, it has
been shown that FXR knock-out mice have a
compromised intestinal architecture, with consequent
bacterial translocation across the epithelial barrier and
recruitment of macrophages/neutrophils [Inagaki et al.,
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susceptibility to CRC by further promoting WNT signaling
via TNFα released by macrophages infiltrating into the
intestinal mucosa because of altered gap-junctions
[Modica et al., 2008].
Besides acting as an indirect oncosuppressor gene and
maintaining the integrity of the intestinal mucosa barrier,
activation of FXR also leads to a more direct
oncosuppressing activity by blocking tumor growth in a
xenograph mouse model [Modica et al., 2008]. Activated
FXR reduces proliferation and induces apoptosis in
colorectal cancer cells by increasing the mRNA levels of
pro-apoptotic genes, such as P21, BCL-2 antagonist killer
1 (BAK1), FAS, Fas-associated death domain (FADD),
and by decreasing the expression of anti-apoptotic genes,
such as B cell lymphoma gene-2 (BCL2) and TNFα.
Likewise, it has been shown that FXR also induces
apoptosis in breast cancer [Swales et al., 2006] and in
the vasculature [Bishop-Bailey et al., 2004].
In summary, it is unlikely that the intestinal tumor
promoting activity of BAs is mediated by FXR, whose
expression is reduced in ACFs. For this reason, FXR may
be considered a new early diagnostic marker for CRC
development. Moreover, the absence of FXR contributes
to the increase of CRC susceptibility both directly, by
inducing apoptotic events, and indirectly, by maintaining
the integrity of the intestinal mucosa barrier.Thus, FXR
may also be considered an intestinal oncosuppressor.
Although the loss of FXR, and not merely elevated BA
concentrations, increase susceptibility to intestinal
tumorigenesis under a normal diet, FXR-independent
tumor promoting activity of toxic high levels of BAs
because of a long-term “Western-style” diet should also
be considered for the pathogenesis of CRC. After
mutation of the APC gene, FXR expression would be
decreased with further promotion of intestinal
tumorigenesis. In this scenario, a long-term
“Western-style” diet would produce high levels of toxic
BAs that will not be buffered by the detoxification activity
of FXR and will be free to promote CRC via
FXR-independent mechanisms. As a result, a high-fat
diet will reduce the time window for the manifestation of
CRC.
Atherosclerosis
The initial finding that FXR knock-out mice exhibit a
pro-atherogenic lipid profile, having increased plasma
TGs, FFA and LDL levels [Sinal et al., 2000], suggests a
protective role for FXR in atherosclerosis. However, these
mice did not show features of atherosclerosis even when
fed high-fat/cholesterol diets [Hanniman et al., 2005;
Zhang et al., 2006b].To investigate the role of FXR in
atherosclerosis, FXR knock-out mice were crossed with
two genetic mouse models of accelerated atherosclerosis,
the ApoE- [Guo et al., 2006; Hanniman et al., 2005] and
the LDLR-deficient mice [Zhang et al., 2006b] and fed
with a Western diet. Female FXR
-/-/ApoE
-/- mice presented
less severe atherosclerosis compared to ApoE
-/- control
mice [Guo et al., 2006]. In contrast, male FXR
-/-/ApoE
-/-
mice presented more severe atherosclerosis than ApoE
-/-
control mice [Hanniman et al., 2005]. Indeed, compared
to LDLR
-/- mice, male FXR
-/-/LDLR
-/- exhibit decreased
aortic atherosclerotic lesions [Zhang et al., 2006b].The
atheroprotective effects of FXR deficiency in female
FXR
-/-/ApoE
-/- mice and male FXR
-/-/LDLR
-/- mice may be
due to decreased LDL-cholesterol, although the
mechanism resulting in this reduction remains unclear.
In line with this hypothesis, female FXR
-/-/LDLR
-/- mice
did not display reduced atherosclerotic lesions and did
not have reduced LDL-cholesterol levels.Taken together,
these data suggest that the effect of the loss of FXR on
atherosclerosis is dependent on the genetic background
and on the sex of the animal.
In addition to the impact of FXR on cardiovascular risk
factors such as dyslipidemia and hyperglycemia, FXR
may also have an effect on the arterial wall. It has been
demonstrated by western blot and immunohistochemical
analysis that FXR is expressed in vascular smooth muscle
cells (VSMCs) in human vessels and in atherosclerotic
lesions [Bishop-Bailey et al., 2004]. Activation of FXR by
GW4064 and 6α-ECDCA resulted in the induction of SHP
and PLTP in rat smooth muscle cells (RASMCs) [Li et
al., 2007; Zhang et al., 2008]. However, since these
effects were not always confirmed with CDCA
[Bishop-Bailey et al., 2004; Zhang et al., 2008], it cannot
be excluded that FXR ligands, other than BAs, may exist
outside the enterohepatic circulation. Interestingly,
6α-ECDCA and GW4064 blunt the VSMCs inflammatory
response and migration by inhibiting IL1β-induced
expression of cyclooxygenase-2 (COX2) and iNOS in
RASMCs, an effect achieved by decreasing NF-κB in a
SHP-dependent way [Li et al., 2007] (Table 1).
Furthermore, activation of FXR promotes apoptosis in
RASMC cells and reduces their migration induced by
platelet-derived growth factor (PDGF)-β [Li et al., 2007].
Finally, FXR activation induces the expression of
angiotensin type 2 receptor (AT2R) (Table 1) in RASMCs,
which results in inhibition of angiotensin II-mediated ERK
signaling [Zhang et al., 2008]. Notably, overexpression
of AT2R and inhibition of the ERK signaling has been
proposed to partially mediate the hypotensive effects of
AT1R blockers [Savoia et al., 2007] and prevent
neointimal proliferation [Nakajima et al., 1995]. Although
FXR activity does not impact on AT1R expression in
RASMCs, CDCA represses angiotensinogen in a
SHP-dependent fashion in hepatocytes [Shimamoto et
al., 2004]. Overall, FXR activation in VSMCs may have
some benefit on blood pressure, vascular inflammation
and neointimal proliferation.
Low expression levels of FXR were also detected in
several endothelial cells such as human pulmonary artery
endothelial cells (HPAEC) [Qin et al., 2006], rat (RPAEC)
[He et al., 2006], bovine aortic endothelial cells (BAEC)
[Li et al., 2008] and primary human umbilical vein
endothelial cells (HUVEC) [Qin et al., 2006]. Despite the
low expression levels, activation of endothelial FXR by
CDCA seems to be functional. FXR activation reduced
the expression of endothelin-1 (ET-1) (Table 1), a
vasoconstrictive peptide, with possible beneficial effects
against atherosclerosis [He et al., 2006]. Further beneficial
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FXR directly induced the endothelial nitric oxide synthase
(eNOS) (Table 1) gene promoter to increase the NO
production in vascular endothelial cells [Li et al., 2008].
In line with these observations, reduced activity of
vasoconstrictors and arterial hypotension has been
reported in cirrhotic patients with high levels of circulating
BAs [MacGilchrist et al., 1991]. On the other hand, CDCA
treatment increases the expression of the adhesion
molecules such as intracellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1), which promote macrophage recruitment to
the endothelium, a crucial process for atherosclerosis
development [Qin et al., 2006]. However, GW4064
treatment only increases the expression of adhesion
molecules at high concentrations and still to a lesser
extent than CDCA.This suggests an FXR-independent
activity of CDCA on ICAM-1 and VCAM-1 expression.
Taken together, the data concerning the role of FXR in
the vasculature tissue should be carefully judged.The
levels of FXR expression are in fact very low in this tissue
making it unlikely that BAs would activate FXR in vivo
under physiological conditions. Indeed, FXR activation
in this tissue requires high doses of its specific synthetic
ligand GW4064.
FXR can also affect vascular function through its hepatic
activity. In vitro experiments on human hepatocytes
displayed that FXR activation is able to induce the
expression of the human ICAM-1 promoter [Qin et al.,
2006] (Table 1). Moreover, mice treated with CA exhibit
increased levels of ICAM-1 and VCAM-1.These findings
suggest that hepatic FXR activation may be associated
with promotion of the atherogenic process. On the other
hand, recent data indicate that FXR activation in human
hepatocytes induces the expression of kininogen [Zhao
et al., 2003] and bradykinin [Margolius, 1996] (Table 1).
Kininogen is a precursor of the two-chain kinin free
kininogen, which has anti-inflammation, anti-adhesion
and anti-platelet aggregation activities, and bradykinin is
a potent vasodilator.Therefore, induction of these two
molecules may contribute to the antithrombotic activity
of FXR.
In contrast, it has been shown that FXR activation induces
the expression of fibrinogen, a key molecule in the
coagulation pathway proposed as a cardiovascular risk
factor [Scarabin et al., 2003], in an isoform-dependent
manner [Anisfeld et al., 2005]. Furthermore, FXR
activation decreases hepatic paraoxonase 1 (PON1)
expression (Table 1), an enzyme associated with HDL
that prevents LDL oxidation, with consequent
anti-inflammatory atheroprotective effects [Gutierrez et
al., 2006; Shih et al., 2006]. It has been shown that, as
for CYP7A1, FXR-mediated repression of PON1 involves
the induction of FGF19 for the activation of the
FGFR4-JNK pathway [Gutierrez et al., 2006; Shih et al.,
2006].Thus, intestinal FXR activation may promote
atherosclerosis by repressing both CYP7A1 and PON1
via FGF19.
Conclusions
Starting from its initial cloning in 1995, the knowledge of
the different functions of FXR has expanded rapidly. It is
now recognized that activation of FXR not only has an
impact on the homeostasis of BAs, which are the
endogenous FXR ligands, but also affects lipid and
glucose metabolism.Therefore, modulation of FXR
activity may be exploited for the pharmacologic
management of metabolic disorders related to BA and
lipid/glucose metabolism, such as cholestasis, CGD,
intestinal bacterial overgrowth, hepatic and intestinal
tumorigenesis, dyslipidemia, hypertriglyceridemia,
diabetes and atherosclerosis. From a theoretical point of
view, targeting FXR may also be beneficial to treat all
aspects of the metabolic syndrome, a complex cluster of
cardiovascular disease risk factors including dyslipidemia,
insulin-resistance, increased blood pressure, visceral
obesity and hypercoagubility. However, activation of FXR
may have several possible undesirable effects. For
instance, activation of FXR in order to reduce TG levels
in hypertriglyceridemic patients would also result in
decreased HDL levels and accumulation of cholesterol
in the body, as a consequence of the inhibition of BA
synthesis. Also, treatment of cholestatic subjects with an
FXR activator would have some beneficial effects by
reducing BA synthesis, and increasing BA secretion into
bile, as well as some side effects by reducing hepatic
basolateral secretion of BAs. In this complex scenario,
where activation of FXR integrates beneficial effects and
potentially undesirable side effects, the identification of
tissue-specific gene-selective FXR modulators represent
an intriguing pharmacologic approach to target a specific
cluster of genes avoiding detrimental side effects.
Differences in the docking of the FXR ligands in the four
FXR subtype receptors account for differences in
corepressor dislodgement and/or coactivator recruitment
in a tissue-specific manner, which could be responsible
for the ability of a certain ligand to act as an agonist or
antagonist for a certain gene. In the near future, more
studies focusing on this aspect of FXR activation will be
required to develop ad hoc FXR modulators.
Nevertheless, we now have selective FXR agonists in
the pipeline, but data obtained in human subjects in
relation to the metabolic diseases are needed to verify
the long list of positive or negative results observed in
the different animal models.The toxicity issues have now
been covered and at 14 years from the cloning of FXR,
a novel nuclear receptor ligand is ready to enter the clinic.
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